---
title: Contents
---

import Expander from "../../../src/components/Expander"

- **1.** [Introduction](/antipsychotics/CON155606_2)
  - **1.1** [Class members](/antipsychotics/CON155606_3)
- **2.** [Prescribing points](/antipsychotics/CON155606_4)
  - **2.1** [Adherence to treatment](/antipsychotics/CON155606_5)
  - **2.2** [Children and adolescents](/antipsychotics/CON155606_6)
- **3.** [Principal risks and risk-reduction measures](/antipsychotics/CON155606_7)
  - **3.1** [Gastrointestinal adverse effects](/antipsychotics/CON155606_8)
  - **3.2** [Central nervous system adverse effects](/antipsychotics/CON143740_9)
    - **3.2.1** [Sedation and sleep disturbances](/antipsychotics/CON155606_10)
    - **3.2.2** [Extrapyramidal side effects: introduction](/antipsychotics/CON155606_11)
      - **3.2.2.1** [Extrapyramidal side effects: acute dystonia](/antipsychotics/CON155606_12)
      - **3.2.2.2** [Extrapyramidal side effects: akathisia](/antipsychotics/CON155606_13)
      - **3.2.2.3** [Extrapyramidal side effects: parkinsonism](/antipsychotics/CON155606_14)
      - **3.2.2.4** [Extrapyramidal side effects: tardive dyskinesia](/antipsychotics/CON155606_15)
    - **3.2.3** [Neuroleptic malignant syndrome](/antipsychotics/CON155606_16)
    - **3.2.4** [Convulsions](/antipsychotics/CON155606_17)
  - **3.3** [Cardiovascular adverse effects](/antipsychotics/CON155606_18)
    - **3.3.1** [Blood pressure changes](/antipsychotics/CON155606_19)
    - **3.3.2** [Cerebrovascular events such as stroke](/antipsychotics/CON155606_20)
    - **3.3.3** [Cardiac rhythm disordersâ€”QT interval prolongation](/antipsychotics/CON155606_21)
    - **3.3.4** [Venous thromboembolism](/antipsychotics/CON155606_21)
  - **3.4** [Metabolic adverse effects](/antipsychotics/CON155606_23)
  - **3.5** [Hyperprolactinaemia and sexual adverse effects](/antipsychotics/CON155606_24)
  - **3.6** [Blood disorders](/antipsychotics/CON155606_25)
  - **3.7** [Temperature regulation](/antipsychotics/CON155606_26)
  - **3.8** [Adverse effects on the skin](/antipsychotics/CON155606_27)
  - **3.9** [Adverse effects on the eye](/antipsychotics/CON155606_28)
  - **3.10** [Antimuscarinic adverse effects](/antipsychotics/CON155606_29)
  - **3.11** [Dependence and withdrawal](/antipsychotics/CON155606_30)
  - **3.12** [Important drug interactions](/antipsychotics/CON155606_31)
- **4.** [Precautions and risks associated with special uses of antipsychotics](/antipsychotics/CON155606_32)
  - **4.1** [Elderly patients with dementia](/antipsychotics/CON155606_33)
  - **4.2** [Pregnancy and breastfeeding](/antipsychotics/CON155606_34)
  - **4.3** [Prolonged-release antipsychotic injections](/antipsychotics/CON155606_35)
  - **4.4** [Antipsychotic injections for immediate effect](/antipsychotics/CON155606_36)
  - **4.5** [Clozapine](/antipsychotics/CON155606_37)
- **5.** [Key points](/antipsychotics/CON155606_38)
- **6.** [Further information](/antipsychotics/CON155606_39)
- **7.** [Summary of licensed indications of antipsychotics for adults](/antipsychotics/CON155606_40)
- **8.** [Classification of antipsychotics](/antipsychotics/CON155606_41)
- **9.** [Structural formulae of selected antipsychotics](/antipsychotics/CON155606_42)
- **10.** [Self-assessment questions](/antipsychotics/CON155606_43)
  - **10.1** [Feedback on self-assessment questions](/antipsychotics/CON155606_44)
- **11.** [Glossary](/antipsychotics/CON155606_45)
- **12.** [Module evaluation](/antipsychotics/CON155606_46)
